^
    Back
    Association details:
    Biomarker:EGFR-RAD51 fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2018
    Title:

    Prevalence of EGFR gene fusions in a large cohort of Chinese patients with non-small cell lung cancer (NSCLC).

    Published date:
    05/16/2018
    Excerpt:
    The second patient: EGFR-RAD51 fusion driven NSCLC responding to erlotinib will be presented...The patient was considered to have a partial response (PR) to erlotinib.
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Lung Cancer
    Title:

    EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report

    Excerpt:
    Then the patient experienced a remarkable tumor response to erlotinib. Considering this rare EGFR fusion and remarkable response to TKI treatment, we conclude that the incidence of EGFR fusions in NSCLC patients should be attentive.
    DOI:
    10.1016/j.lungcan.2017.12.001